Niagen Bioscience, Inc.
NAGE evidence brief
What we can confirm
- BioSniper Score:
- 4.8 / 10
- Market Cap:
- $222.2M
- Lead Asset:
- niagen (Preclinical)
What it means
What to watch
Prepared research question
What matters most for NAGE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NAGE
Niagen Bioscience, Inc. (NAGE) is a publicly traded company focused on NAD+ biology and healthy aging, with a platform spanning consumer supplements (Tru Niagen®), ingredient supply, and pharmaceutical development of the investigational candidate NB4168 for rare genetic diseases.
Key risk: Preclinical stage of NB4168
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$222.2M
Cash Runway
—
Lead Asset
niagen (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Niagen Bioscience, Inc..
Niagen Bioscience, Inc. (NAGE) is a publicly traded company focused on NAD+ biology and healthy aging, with a platform spanning consumer supplements (Tru Niagen®), ingredient supply, and pharmaceutical development of the investigational candidate NB4168 for rare genetic diseases.
- Total revenue of $29.8M and net income of $1.0M as of 2026-06-30 [sec].
- Shareholders' equity of $82.5M as of 2026-06-30 [sec].
- Surpassed 300 material transfer agreements (MTAs) with global research institutions, contributing to 45 published clinical studies as of March 2026 [news].
- Entered a Start-Up Agreement with Mass General Brigham in September 2026 to plan a large clinical trial of Niagen [news].
- NB4168, a proprietary NR-based candidate for Ataxia-Telangiectasia, received Rare Pediatric Disease designation from the FDA and Orphan Medicinal Product Designation from the EMA as of August 2026 [sec_mda].
What works
- Strong financial position with $82.5M in shareholders' equity and low debt, providing flexibility for R&D and operations [sec].
- Extensive external research network with over 300 MTAs and 45 published clinical studies, supporting the scientific foundation of Niagen [news].
- Regulatory milestones for NB4168 (RPD from FDA, OMPD from EMA) de-risk the rare disease drug development path [sec_mda].
- Partnership with Mass General Brigham for a large-scale healthy aging trial signals institutional credibility and potential for broad clinical validation [news].
What to weigh
- NB4168 is still in preclinical stage, with no clinical data yet available; drug development carries inherent risk of failure [pipeline].
- The company's forward-looking statements are subject to risks and uncertainties, and it undertakes no obligation to update them [sec_mda].
- Dependence on a single proprietary ingredient (Niagen) for both consumer products and pharmaceutical development creates concentration risk [sec_mda].
- The competitive landscape for NAD+ precursors includes large pharmaceutical companies, biotech firms, and academic institutions, which may limit market share [pipeline].
From the filings
Quoted directly from source documents.
NB4168 received Rare Pediatric Disease designation from FDA and Orphan Medicinal Product Designation from EMA
“the U.S. Food and Drug Administration granted Rare Pediatric Disease (RPD) designation for NB4168 for the treatment of AT, and the European Medicines Agency (EMA) granted Orphan Medicinal Product Designation (OMPD) for NB4168”
SEC MD&A · August 4, 2026
External research program surpassed 300 MTAs and contributed to 45 published clinical studies
“its external research program has surpassed 300 material transfer agreements (MTAs) with investigators and research institutions around the world, marking a major milestone for what the Company believes is the most extensive dedicated NAD+ research support progr”
News · March 17, 2026
Start-Up Agreement with Mass General Brigham to plan a large clinical trial of Niagen
“today announced a Start-Up Agreement with Mass General Brigham (MGB) to begin detailed planning for what is envisioned to be the largest and most comprehensive clinical trial of Niagen (patented nicotinamide riboside or NR) to date.”
News · September 30, 2026
Risks & what to watch (4)›
Key risks
- Preclinical stage of NB4168 — NB4168 is still preclinical; no clinical data yet, and drug development carries inherent risk of failure [pipeline].
- Forward-looking statement uncertainties — Company disclaims obligation to update forward-looking statements, which are subject to risks and uncertainties [sec_mda].
- Ingredient concentration risk — Both consumer and pharma segments depend on a single proprietary ingredient (Niagen), creating concentration risk [sec_mda].
- Competitive landscape — NAD+ precursor space includes large pharma, biotech, and academic competitors, which may limit market share [pipeline].
What to watch
- Progress of the Mass General Brigham clinical trial for Niagen, including enrollment and initial results [news].
- Advancement of NB4168 into clinical trials, given its RPD and OMPD designations [sec_mda].
- Financial performance trends, especially revenue growth and net income, as the company expands its pharmaceutical pipeline [sec].
- Any new partnership or licensing deals that could broaden the Niagen platform beyond current consumer and rare disease applications [news].
Sources: News · Pipeline · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run Niagen Bioscience, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Niagen Bioscience, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.29 · 4% dilution
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Short Interest
as of Apr 21, 2026- % of float
- 10.4%
- Days to cover
- 3.3
- Shares short
- 5,496,661
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NAGE short interestGovernance
Frequently asked questions
What is the AI investment thesis for Niagen Bioscience, Inc.?
Niagen Bioscience, Inc. (NAGE) is a publicly traded company focused on NAD+ biology and healthy aging, with a platform spanning consumer supplements (Tru Niagen®), ingredient supply, and pharmaceutical development of the investigational candidate NB4168 for rare genetic diseases.
What is Niagen Bioscience, Inc.'s lead drug candidate?
Niagen Bioscience, Inc.'s most advanced tracked candidate is niagen (Preclinical) for rare advanced aging diseases.
Who is the CEO of Niagen Bioscience, Inc.?
Mr. Robert N. Fried is the chief executive officer of Niagen Bioscience, Inc. (NAGE).
Where is Niagen Bioscience, Inc. headquartered?
Niagen Bioscience, Inc. (NAGE) is headquartered in Los Angeles, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.